Peripheral T-Cell Lymphoma

MARSEILLE, France I April 29, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload, approved for urothelial carcinoma (UC), an indication with high Nectin-4 expression. However, EV discontinuation due to toxicity, disease relapse, or treatment ineligibility, along with its limited efficacy in tumors with lower Nectin-4 expression, underscores the need for a differentiated Nectin-4 ADC with improved therapeutic window and improved mechanisms of action. IPH4502 demonstrated anti-tumor activity in EV-resistant patient-derived xenograft (PDX) model with upregulation of multi-drug resistance protein 1 (MDR1), supporting its potential to overcome resistance mechanisms in EV-refractory disease. Beyond UC, IPH4502 also exhibited anti-tumor activity in preclinical models of triple-negative breast cancer, head and neck squamous cell carcinoma, and esophageal cancer, suggesting broader potential clinical applicability. In addition, in preclinical tumor models with low Nectin-4 expression, IPH4502 showed superior anti-tumor activity compared to a clinical-stage Nectin-4-exatecan ADC supported by higher internalization, cytotoxicity, and bystander killing effect. “ We are highly encouraged by these preclinical data, which suggest that IPH4502 has the potential to translate into improved clinical benefit in indications with unmet medical need. These findings also reinforce the rationale for our ongoing Phase 1 trial. We look forward to sharing initial clinical data in 2026 as the program advances, ” said Sonia Quaratino, Chief Medical Officer of Innate Pharma . IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors known to express Nectin-4 ( NCT06781983 ). The poster is available on Innate Pharma’s website . About IPH4502 IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer. IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients. In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate’s portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com . Follow us on LinkedIn and X . SOURCE: Innate Pharma

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As part of these discussions, Sanofi and Innate have agreed to a potential investment by Sanofi of up to €15M in new shares of Innate. The size and price of this equity investment will be determined on the basis of the ongoing market conditions, if they are satisfactory. The 2022 research collaboration and license agreement remain unchanged. “We are very pleased that Sanofi has chosen to further strengthen our relationship through a potential strategic equity investment in the company. This would further validate the innovation and scientific progress at Innate Pharma delivered by our research and development. We acknowledge Sanofi’s portfolio prioritization, and we are encouraged to see our ANKET ® platform being pursued in autoimmune indications. We will continue to evaluate, plan and execute next steps for our proprietary ANKET ® programs in oncology and beyond,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. SAR’579 (NCT05086315)/IPH6101 SAR’514/IPH6401: IPH62 and one additional target About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate’s portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X . SOURCE: Innate Pharma

Dublin, Ireland, April 6 2025 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, autoimmune and inflammatory diseases today announced the publication of a paper showing pre-clinical data on the company’s first-in-class dual PIM/PI3K inhibitor, IBL-202, as a potential treatment for mature T-cell lymphoma (mTCL). The paper titled “Dual targeting of Pim and PI3 kinases in mature T-cell lymphoma” provides mechanistic evidence supporting dual inhibition of PIM- and PI3-kinases as a novel therapeutic strategy in mTCL can be accessed at https://onlinelibrary.wiley.com/doi/10.1111/ejh.14420. The data was generated through a collaboration between Inflection and the University Medical Center, Göttingen, Germany, led by PD Dr. med. Raphael Koch, Max-Eder Research Group Leader, Hematology and Oncology. The collaboration was funded by Inflection Biosciences, University Medical Center, Göttingen, German Research Foundation (DFG), German Cancer Aid and Volkswagen Foundation. Dr. Raphael Koch commented “The data shows that the dual inhibition of PIM kinases and the PI3K/AKT pathway is a promising therapeutic strategy for mTCL. One challenging factor in mTCL treatment is the heterogeneity of this entity, making it hard to find drugs that target the different subtypes. IBL-202 showed cytotoxic effects on all tested mTCL lines, across different subtypes.” Mature T-cell lymphoma is as a diverse subgroup of aggressive non-Hodgkin lymphomas that develop from mature white blood cells (T-cells) or natural killer (NK) cells. Due to specific clinical pictures, the different subtypes are considered as separate diseases, carrying different genetic profiles. According to the World Health Organisation, the majority of peripheral T-cell lymphoma subtypes have poor prognosis, with a 5-year overall survival of about 30%. About Inflection Biosciences Inflection Biosciences Ltd. is developing small molecule therapeutics for the treatment of cancer, autoimmune and inflammatory diseases. AUM302, partnered with AUM Biosciences, is a first-in-class PIM/PI3K/mTOR inhibitor in development for the treatment of cancer. IBL-202 is a first-in-class, dual PIM kinase and PI3K inhibitor in development for aggressive B-cell malignancies, T-cell lymphoma and acute myeloid leukemia. IBL-100s is a pan-PIM kinase inhibitor program in preclinical development for the treatment of autoimmune diseases. For more information, please visit www.inflectionbio.com For further information contact: Inflection Biosciences Ltd Darren Cunningham, Director E: dcunningham@inflectionbio.com T: +353 (0)1 4003615